Additional treatment options impact first-line treatment of mRCC: Yes

Discussion: Additional treatment options impact first-line treatment of mRCC

From clinical trial to clinical practice: Evidence from the real world

What have we learned? Expert perspectives

The evolving treatment landscape for HER2-positive metastatic breast cancer

Navigating current treatment options for HER2-positive MBC: Patient journey 1

ecancermedicalscience editor's choice for September 2014

Benefits of investing in skin cancer prevention

Preventing skin cancer worldwide and the impact of different regulatory and economic priorities

Overview of skin cancer treatments, past, present and future

Biomarker found to aid in screening of squamous cell carcinoma

Moles on the skin increase skin cancer risk